401. [Adverse effects of antimetabolite fluoropyrimidine analog].403. [Platinum drugs].404. [Adverse events and those managements of alkylating agents].405. [Mechanisms and side effects of cytotoxic anticancer drugs].406. [Exploratory biomarker analyses and companion diagnostics].407. [Pharmacogenomics of anti-cancer drugs for individual treatment].408. [Biomarkers for the prediction of adverse events].409. [Clinical pharmacology and toxicology of anticancer drugs].410. [Monitoring the side effects of cancer chemotherapy].411. [Patient education for side effects of anti-cancer agents].412. [Prophylactic management for adverse events of cancer chemotherapy].413. [Drug interactions of anti-cancer agents].414. [Reduction and withdrawal of chemotherapy].415. [Assessment of anticancer drug-induced adverse event].416. [Report of serious adverse drug reaction induced by anti-cancer agents].417. [Safety management in the outpatient chemotherapy unit].418. [Important points of measures for side effects in children].419. [Points of management for elderly patients in chemotherapy].420. [Clinical practice guidelines for the adverse events in medical oncology]. |